8-KOther Events

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Dec 17, 2004)

Filed December 17, 2004For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on December 17, 2004, to report the outcome of a special shareholder meeting held the same day. The primary purpose of the meeting was to vote on a proposal to amend the Company's 2000 Long-Term Incentive Plan. Shareholders approved this amendment, which specifically authorizes an Option Exchange Program previously detailed in the company's Schedule 14A proxy statement filed on November 29, 2004. This shareholder approval is a key corporate governance event, enabling the company to implement a new equity incentive program. Investors should note that the details of the Option Exchange Program were outlined in the prior proxy filing, and this 8-K serves as notification of the successful shareholder ratification. This action is generally taken to align employee incentives with long-term company performance and shareholder value.

Key Highlights

  • 1Shareholders approved an amendment to the 2000 Long-Term Incentive Plan.
  • 2The approved amendment expressly authorizes the Option Exchange Program.
  • 3The Option Exchange Program was previously detailed in the company's Schedule 14A proxy statement filed on November 29, 2004.
  • 4The special shareholder meeting took place on December 17, 2004.
  • 5This filing is an 8-K Current Report, indicating a significant corporate event.
  • 6The approval signifies a step towards implementing a new equity incentive mechanism for employees.

Frequently Asked Questions

The main purpose was for shareholders to vote on and approve an amendment to Regeneron's 2000 Long-Term Incentive Plan. This amendment was specifically to authorize the Option Exchange Program.

The Option Exchange Program is a new equity incentive initiative that the company sought shareholder approval to implement. Details regarding its structure and purpose were provided in the company's proxy statement filed on November 29, 2004.

Shareholder approval is typically required for amendments to long-term incentive plans, especially when introducing new programs like an option exchange, to ensure proper corporate governance and alignment with shareholder interests. It's a common practice for publicly traded companies.

More detailed information about the Option Exchange Program can be found in Regeneron's definitive proxy statement on Schedule 14A, which was filed with the SEC on November 29, 2004.